Lorenzo BallPedro Leme SilvaDaniele Roberto GiacobbeMatteo BassettiGustavo Zubieta‐CallejaPatrícia R. M. RoccoPaolo Pelosi2026-03-222026-03-22202210.1080/17476348.2022.2057300https://doi.org/10.1080/17476348.2022.2057300https://andeanlibrary.org/handle/123456789/85592Citaciones: 34ARDS is defined as a syndrome rather than a distinct pathologic entity. There is great heterogeneity regarding the pathophysiologic, clinical, radiologic, and biological phenotypes in patients with ARDS, challenging clinicians, and scientists to discover new therapies. COVID-19 has been described as a cause of pulmonary ARDS and has reopened many questions regarding the pathophysiology of ARDS itself. COVID-19 lung injury involves direct viral epithelial cell damage and thrombotic and inflammatory reactions. There are some differences between ARDS and COVID-19 lung injury in aspects of aeration distribution, perfusion, and pulmonary vascular responses.enARDSMedicinePathophysiologyPneumoniaIntensive care medicineDiffuse alveolar damageCoronavirus disease 2019 (COVID-19)Respiratory failureViral pneumoniaCoronavirusreview